DURYSTA Implant

The FDA approved the DURYSTA implant in June 2020 for the treatment of open-angle glaucoma. DURYSTA.Recommendations and consent discusses the risk of endothelial cell loss (ECL), and provides a sample consent form to help educate patients about the risks and benefits. Both the recommendations and consent form address implanting more than one DURYSTA per eye.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.